
The
traditional medical approach of lowering low-density lipoprotein
(LDL) or "bad cholesterol" may not be enough to reduce the risk
of cardiovascular disease, according to a respected Australian
cardiologist. "Studies show that a considerable risk of
cardiovascular disease remains even with optimal LDL reduction.
Evidence is accumulating that triglycerides and high-density
lipoprotein [HDL] should be therapeutic targets as well," says
Dr. Paul Nestel, professor of Medicine at the Baker Heart
Research Institute and Deakin University in Melbourne.
LDL, triglycerides, and HDL - the so called
"good cholesterol" - are lipids, fat-like substances present in
the blood. Most of the lipids in the body are manufactured by
the liver while some come from our diet. When levels of LDL
and/or triglycerides rise or HDL fall below normal levels, a
condition called dyslipidemia develops.
Dyslipidemia contributes to the narrowing,
hardening and clogging of arteries (atherosclerosis) that can
lead to heart attack and stroke.
For patients with dyslipidemia, doctors often
initially recommend lifestyle modification that includes eating
a healthy diet, quitting smoking, exercising regularly, and
maintaining an ideal weight.
For patients who are unable to modify their
lifestyle or in whom lifestyle modification is unable to address
dyslipidemia, doctors usually prescribe a type of
lipid-modifying drug called statin.
"However, statins primarily target LDL
only,"says Dr. Nestel, "and studies show that even with optimal
lowering of LDL, there is a substantial residual risk of
cardiovascular disease. This indicates a need for further
interventions on lipids and lipoproteins."
Dr. Nestel says evidence is accumulating that
lowering triglycerides and increasing HDL levels, on top of
standard LDL lowering, is a more effective way of reducing
cardiovascular disease risk.
"Ideally, you should aim for an HDL level of
at least 39 mg/dl," he says Dr. Nestel. "Studies have shown that
for every 1 mg/dL rise in HDL, your risk of developing
cardiovascular disease decreases by 2 to 3 perecent."
According to the latest National Nutrition
and Health Survey conducted by the Food and Nutrition Research
Intsitute, one out of two Filipino adults has an HDL level below
35 mg/dl.
Among the currently available lipid-modifying
drugs, statins give the highest LDL reduction (up to 55 percent)
while fibrates offer the best triglyceride lowering capability
(up to 50 percent). "But niacin is the most effective HDL-raising
agent, capable of boosting good cholesterol levels by up to 35
percent," says Dr. Nestel. "Plus niacin offers other
lipid-modifying effects, with an LDL-lowering effect of up to 25
percent and triglyceride-lowering capability of up to 50
percent."
Unfortunately, previous formulations of
niacin cause several side effects, the most bothersome of which
is flushing. Flushing is the dilation of blood vessels causing
redness of the skin coupled with a warming or burning sensation
on the face and neck. It is believed that niacin induces the
flushing response by triggering the release of prostaglandin D2
(PGD2), a chemical that causes dilation of blood vessels in the
skin and flushing symptoms. The understanding of this mechanism
opened the possibility of lessening the flushing effect produced
by niacin, through new pharmacologic intervention.
"Combined with standard lipid-modifying drugs, niacin can
help address the unmet need of increasing HDL among dyslipidemic
patients to further reduce their cardiovascular disease risk,"
says Dr. Nestel.